




First-in-class Opportunity in Cardiovascular and Metabolic Diseases



Smart drug development

Speedel develops novel therapies through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing.



Speedel (SWX: SPPN) is a biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases.

Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases.

At the heart of value creation™

Speedel seeks to create, enhance and unlock value in the following ways:

- Create value with its late-stage research unit Speedel Experimenta by generating new compounds and intellectual property through focused lead identification and optimization programmes
- Enhance value by taking over projects from biotech or research start-ups lacking drug development skills and financial strength
- Unlock value of projects in-licensed from big pharma, which, due to technical and/or strategic reasons are not fully resourced

Proven management track record

Speedel has a team of approximately 75 employees, including over 40 experienced pharmaceutical scientists, who are located at our headquarters and laboratories in Basel, Switzerland, and at offices in New Jersey, USA and Tokyo, Japan.

The management team combines the best of both worlds: big pharma top quality standards and biotech entrepreneurial dynamism. With an average of over 15 years experience in the pharmaceutical and biotech industries, this team has collectively contributed to the development of pharmaceuticals that today generate more than USD 5 billion in annual sales (including Diovan®, Sandimmune® / Neoral®, Femara®, all marketed by Novartis).

Solid financial base

Speedel (SWX: SPPN) in January 2007 raised gross proceeds of CHF 55.5 million (EUR 34.3 m or USD 44.5 m approx.) through a convertible bond issue. In March 2006 the company raised gross proceeds of CHF 83.95 million (EUR 53m or USD 64m approx.) through the public offering of 500,000 treasury shares. As a private company, it raised gross proceeds of CHF 255 million (EUR 157 m or USD 204 m approx.) from private placements of equity securities and two convertible loans including the conversion premiums. The company has earned total revenues, principally from milestone payments, of CHF 57.7 million (EUR 37 m or USD 44 m approx.).

CHF million	Year ended December 31				H1
	2003	2004	2005	2006	2007
Revenues	3.0	-	-	-	1.0
Research and Development	(21.0)	(28.1)	(52.9)	(73.5)	(33.8)
Total Operating Expenses	(25.0)	(33.4)	(63.8)	(85.6)	(39.5)
Loss for the period	(23.4)	(37.6)	(65.4)	(91.1)	(38.2)
Liquid assets ⁽¹⁾	68.4	42.3	101.1	121.1	134.8
Interest bearing liabilities ⁽²⁾	43.2	46.7	62.1	6.1	49.6
Total equity	22.6	(8.7)	30.3	100.1	75.6
Cash-burn ⁽³⁾	30.3	34.4	59.5	75.1	41.9
Number of Employees (Headcount)	40	61	68	75	75

(1) Includes cash and cash equivalents and financial assets held at fair value through profit or loss (2) Includes borrowings, finance lease payable and convertible loans (3) Cash-burn is defined as the difference in liquid assets between the beginning and end of the period, minus any cash inflow during the period

Founded: 1998
CEO & Founder:
Dr Alice Huxley
CFO: Konrad P. Wirz
Employees: 75
Intellectual Property:
Applications filed for 74 patent families of which 27 patents have been granted.

www.speedel.com

Mature and diverse pipeline targeting significant indications

Cardiovascular and metabolic diseases represent some of the most significant unmet medical needs today. Speedel is focused on producing innovative therapies for meeting these needs. Our current pipeline covers three different modes of action and includes one potential blockbuster product on the market, one candidate in Phase III, two product candidates in Phase II, one candidate in Phase I, plus several pre-clinical products.

- The most advanced product candidate is SPP100, the **first-in-class** renin inhibitor that is being developed by our partner Novartis as a monotherapy and combination therapy for the treatment of hypertension. It was approved by the US FDA in March 2007 and by the EMEA in the EU in August 2007.
- SPP301, an endothelin A receptor antagonist, started Phase III clinical trials for diabetic nephropathy in July 2005; however, the ASCEND Phase III trial was stopped in December 2006 in the interests of patient safety.
- SPP200, a direct thrombin inhibitor, is an anti-coagulant treatment for patients undergoing chronic haemodialysis for end stage renal disease and completed a Phase II trial in the US in Q3 2006.
- SPP635 completed Phase IIa in Q2 2007 in hypertension and is continuing Phase II development in diabetic patients with hypertension. It is one of a new series of proprietary renin inhibitors, which are being developed for the treatment of hypertension and the protection of end organs, such as the kidneys and heart.
- SPP1148, another next generation renin inhibitor, entered Phase I in Q1 2007.

Originator	Lead identification	Lead optimisation	Phase 0	Phase I	Phase II	Phase III	Registration US	Approved US	Approved EU	Disease
Novartis		SPP100			Renin Inhibitor monotherapy					Hypertension NOVARTIS
Novartis		SPP100+HCTZ			Renin Inhibitor + diuretic					Hypertension NOVARTIS
Novartis		SPP100+valsartan			Renin Inhibitor + ARB					Hypertension NOVARTIS
Novartis		SPP100+ramipril			Renin Inhibitor + ACE-I					Hypertension NOVARTIS
Novartis		SPP100+amlodipine			Renin Inhibitor + CCB					Hypertension NOVARTIS
Novartis		SPP100+HCTZ (fixed dose)			Renin Inhibitor + diuretic					Hypertension NOVARTIS
Novartis		SPP100+ramipril			Renin Inhibitor + ACE-I					Diabetic Hypertension NOVARTIS
Novartis		SPP100			Renin Inhibitor					Diabetic Nephropathy NOVARTIS
Novartis		SPP100			Renin Inhibitor					Left Ventricular Hypertrophy NOVARTIS
Novartis		SPP100			Renin Inhibitor					Heart Failure NOVARTIS
Abbott		SPP200			Direct Thrombin Inhibitor					Graft Occlusion in Chronic Hemodialysis
Roche		SPP301			Endothelin A Receptor Antagonist		(on hold)			Diabetic Nephropathy
Speedel		SPP635			Renin Inhibitor					Hypertension & End Organ Protection
Speedel		SPP1148			Renin Inhibitor					Hypertension & End Organ Protection
Speedel		Renin Inhibitor				SPP600 Series				Hypertension & End Organ Protection
Speedel/Locus		Renin Inhibitor				SPP800 Series				Cardiovascular
Speedel		Renin Inhibitor				SPP1100 Series				Hypertension & End Organ Protection

SPP100 + means co-administration with other drug

Significant partnerships

Speedel has successfully established partnerships with leading pharmaceutical and biotechnology companies such as Novartis, Roche and Abbott. Our partnering strategy is to establish collaborations where there is convergence of know-how, opportunity and strategic fit at any stage of the value chain.

First-in-class for Renin Inhibition

Renin is the key enzyme at the top of the Renin Angiotensin System (RAS), one of the key regulators of blood pressure. The RAS is a cascade, starting with renin, leading to angiotensin I and finally to angiotensin II. By inhibiting renin, it is believed that additional benefits over and beyond current therapies will be created for patients suffering from hypertension, chronic renal failure, congestive heart failure and other cardiovascular diseases.

The development of SPP100, an oral renin inhibitor, is the result of over 20 years of industry research on renin. Speedel believes it is the first company to have successfully established clinical efficacy in Phase II and to have developed and filed for patent protection of a commercially viable manufacturing process for a renin inhibitor. Novartis licensed-back SPP100 in 2002 after Speedel successfully completed Phase I and II trials.

Speedel aims to maintain its world leadership in renin inhibition through the research and development of its own novel compounds (e.g. SPP635 and SPP1148), and by leveraging its know-how gained from development of SPP100 and from Roche's complete renin inhibitor programme that was in-licensed in 2001.

Share Trading Information

Speedel Holding Limited

Stock Exchange

SWX Swiss Exchange (Main Segment)

First day of trading

08 September 2005

Market Capitalisation

10 August 2007

CHF 1.3 bn/EURO 0.8 bn/USD 1.1 bn

Shares issued

Go to www.swx.com

SWX Indices

Swiss All Share Index

SPI Family

SPI®

SPI EXTRA®

SPI sectors:

SPI Small Companies

SPI Small and Middle Cap

SPI Registered Share

SPI Biotechnology

SXI Family

SXI Life Sciences®

SXI Bio+Medtech®

Ticker Symbol SPPN

Bloomberg SPPN SW

Reuters SPPN.S

Swiss Security Number

2.148.388

ISIN International Security

Identification Number

CH0021483885

Common Code

021937797

Bond Trading Information

Stock Exchange

SWX Swiss Exchange (Main Segment)

Ticker Symbol SPP07

First trading day on SWX

22 January 2007

Swiss Security Number

2.875.937

ISIN International Security

Identification Number

CH0028759378

Analyst Coverage

Bear Stearns

Deutsche Bank

Helvea

JP Morgan

Lehman Brothers

Merrill Lynch

UBS

Vontobel

For further information,

please contact:

Nick Miles

Director Communications

& Investor Relations

Speedel

Hirschgässlein 11

CH - 4051 Basel

Switzerland

T +41 (0) 61 206 40 00

D +41 (0) 61 206 40 14

F +41 (0) 61 206 40 01

E nick.miles@speedel.com

Frank LaSaracina

Managing Director

Speedel Pharmaceuticals Inc.

1661 Route 22 West

P.O. Box 6532

Bridgewater, NJ 08807

United States of America

T +1 732 537 2290

F +1 732 537 2292

E frank.lasaracina@speedel.com



at the heart of value creation™

www.speedel.com



© Speedel August 2007
Speedel is a registered trademark in USA
and many other jurisdictions.

